Blood pressure drug riociguat tested for Long-Term use in rare lung condition

NCT ID NCT02759419

Completed Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the long-term safety of the drug riociguat (Adempas) in adults with pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs. It included 18 people who had already taken riociguat in earlier Bayer studies. The main goal was to track side effects and see if continuing the drug was safe over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION, PULMONARY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION, PULMONARY

Contacts and locations

Locations

Study site

Besançon, 25030, France
Study site

Brest, F-29609, France
Study site

Le Kremlin-Bicêtre, 94275, France
Study site

Lille, 59037, France
Study site

Rouen, 76031, France
Study site

Seoul, Seoul Teugbyeolsi, 03722, South Korea
Study site

Seoul, Seoul Teugbyeolsi, 05505, South Korea
Study site

Seoul, Seoul Teugbyeolsi, 3080, South Korea
Study site

Seoul, 06351, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.